Cutaneous calcification in patients with end-stage renal disease: A regulated process associated with in situ osteopontin expression

Archives of Dermatology

Volumn 142, Issue 7, 2006, Pages 900-906

  Rivet, Jacqueline ^a,b   Lebbé, Celeste ^a   Urena, Pablo ^b,e   Cordoliani, Florence ^a   Martinez, Franck ^a   Baglin, Anne C ^f   Aubert, Pierre ^g   Aractingi, Selim ^c   Ronco, Pierre ^c   Fournier, Philippe ^d   Janin, Anne ^a,b  

^a SAINT LOUIS HOSPITAL   (France)

^b INSERM   (France)

^c HÔPITAL TENON   (France)

^d Hospital Ouest Parisien   (France)

^e Clinique de l'Orangerie Aubervilliers   (France)

^f FOCH HOSPITAL   (France)

^g Hôpital Saint Louis ^*

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM;

ADULT; AGED; ARTICLE; CALCINOSIS; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SKIN CALCIFICATION;

ADULT; AGED; CALCINOSIS; FEMALE; FRANCE; HUMANS; IMMUNOHISTOCHEMISTRY; KIDNEY FAILURE, CHRONIC; MALE; MEDICAL RECORDS; MIDDLE AGED; OSTEOPONTIN; RETROSPECTIVE STUDIES; SIALOGLYCOPROTEINS; SKIN DISEASES;

EID: 33746053510     PISSN: 0003987X     EISSN: 0003987X     Source Type: Journal    
DOI: 10.1001/archderm.142.7.900     Document Type: Article

References (25)

1. Budisavljevic MN, Cheek D, Ploth DW. Calciphylaxis in chronic renal failure. J Am Soc Nephrol. 1996;7:978-982.
2. Cribier B, Grosshans E. Calcinoses cutanées. Ann Dermatol Venereol. 1992;119:151-168.
3. Kuzela DC, Huffer WE, Conger JD, Winter SD, Hammond WS. Soft tissue calcification in chronic dialysis patients. Am J Pathol. 1977;86:403-424.
4. Llach F. Calcific uremic arteriolopathy (calciphylaxis): an evolving entity? Am J Kidney Dis. 1998;32:514-518.
5. Moe SM, O'Neill KD, Duan D, et al. Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int. 2002;61:638-647.
6. Shao JS, Cheng SL, Charlton-Kachigian N, Loewy AP, Towler DA. Teriparatide (human parathyroid hormone (1-34)) inhibits osteogenic vascular calcification in diabetic low density lipoprotein receptor-deficient mice. J Biol Chem. 2003;278:50195-50202.
7. Kennedy J, Shavelle R, Wang S, Budoff M, Detrano RC. Coronary calcium and standard risk factors in symptomatic patients referred for coronary angiography. Am Heart J. 1998;135:696-702.
8. Mazhar AR, Johnson RJ, Gillen D, et al. Risk factors and mortality associated with calciphylaxis in end-stage renal disease. Kidney Int. 2001;60:324-332.
9. Bleyer AJ, Choi M, Igwemezie B, de la Torre E, White WL. A case control study of proximal calciphylaxis. Am J Kidney Dis. 1998;32:376-383.
10. Schinke T, McKee MD, Karsenty G. Extracellular matrix calcification: where is the action? Nat Genet. 1999;21:150-151.
11. Shen M, Marie P, Farge D, et al. Osteopontin is associated with bioprosthetic heart valve calcification in humans. C R Acad Sci III. 1997;320:49-57.
12. Srivatsa SS, Harrity PJ, Maercklein PB, et al. Increased cellular expression of matrix proteins that regulate mineralization is associated with calcification of native human and porcine xenograft bioprosthetic heart valves. J Clin Invest. 1997;99:996-1009.
13. Ahmed S, O'Neill KD, Hood AF, Evan AP, Moe SM. Calciphylaxis is associated with hyperphosphatemia and increased osteopontin expression by vascular smooth muscle cells. Am J Kidney Dis. 2001;37:1267-1276.
14. Chen NX, O'Neill KD, Duan D, Moe SM. Phosphorus and uremic serum upregulate osteopontin expression in vascular smooth muscle cells. Kidney Int. 2002;62:1724-1731.
15. Hirota S, Asada H, Kohri K, et al. Possible role of osteopontin in deposition of calcium phosphate in human pilomatricomas. J Invest Dermatol. 1995;105:138-142.
16. Contri MB, Boraldi F, Taparelli F, De Paepe A, Ronchetti IP. Matrix proteins with high affinity for calcium ions are associated with mineralization within the elastic fibers of pseudoxanthoma elasticum dermis. Am J Pathol. 1996;148:569-577.
17. Preece MA, O'Riordan JL, Lawson DE, Kodicek E. A competitive protein-binding assay for 25-hydroxycholecalciferol and 25-hydroxyergocalciferol in serum. Clin Chim Acta. 1974;54:235-242.
18. Shepard RM, Horst RL, Hamstra AJ, DeLuca HF. Determination of vitamin D and its metabolites in plasma from normal and anephric man. Biochem J. 1979;182:55-69.
19. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-1483.
20. Chan YL, Mahony JF, Turner JJ, Posen S. The vascular lesions associated with skin necrosis in renal disease. Br J Dermatol. 1983;109:85-95.
21. Chertow GM, Burke SK, Dillon MA, Slatopolsky E. Long-term effects of sevelamer hydrochloride on the calcium x phosphate product and lipid profile of haemodialysis patients. Nephrol Dial Transplant. 2000;15:559.
22. Wilkinson SP, Stewart WK, Parham DM, Guthrie W. Symmetric gangrene of the extremities in late renal failure: a case report and review of the literature. Q J Med. 1988;67:319-341.
23. Grosshans E, Maleville J, Jahn H, Frankhauser J. Prurit pendant des séances répétées d'hémodialyse pour insuffisance rénale chronique. Etiologie et étude histopathologique. Bull Soc Fr Dermatol Syphiligr. 1970;77:828-834.
24. Canfield AE, Farrington C, Dziobon MD, et al. The involvement of matrix glycoproteins in vascular calcification and fibrosis: an immunohistochemical study. J Pathol. 2002;196:228-234.
25. Nitta K, Ishizuka T, Horita S, et al. Soluble osteopontin and vascular calcification in hemodialysis patients. Nephron. 2001;89:455-458.